Yuwen Technology raises $7.4M seed for automated cell manufacturing
What's the deal? Yuwen TechnologyDealroom has a profile for this one. Try Dealroom → has raised 50,000,000 CNY (about $7.4 million) in a seed round, with Shanhui Capital as investor. The company builds life-science automation equipment and was announced as a funded startup in June 2026.
What's the endgame? Incubated by Roone Life Sciences, Yuwen focuses on cell-culture automation, GMP-scenario adaptation, and intelligent cell manufacturing. Its CellMatrix platform targets the full cell-preparation workflow, combining automated handling, robotic transfer, live imaging, and process traceability.
Why now? The startup aims to shift cell manufacturing from what it calls "人工经验型操作," or manual, experience-based work, toward automated, digitised, and standardised production. The funding will go mainly to research and product development.
Why it matters: The round is sizeable for a company founded in 2026, signalling investor confidence in the niche. It also marks a step by parent Roone Life Sciences into higher-end upstream equipment, extending its life-science toolchain.
The signal: China's early-stage capital has stayed active in hard tech and life sciences, with seed rounds ranging from tens of millions to hundreds of millions of yuan. As lab automation and domestic toolchain production draw policy and industry attention, backers are still selecting segments with clear technical barriers.
Read more: IT Juzi
Image credit: Generated with Gemini
